However, despite the great success of this unique approach, most patients develop primary or acquired resistance, calling for other immune modulatory pathways that may act cooperatively or alternatively to PD-1/PD-L1 blockage to augment the success of cancer immunotherapy. The gene discussed is CD274; the disease is cancer.